“If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
Implantable Cardioverter Defibrillators (ICDs), Visia AF MRI. Labeled as the following: || a. Visia AF MRI VR SureScan ICD DF1 (Product No. DVFB1D1); || b. Visia AF MRI VR SureScan ICD DF4 (Product No. DVFB1D4); || EXPANSION: || c. Visia AF MRI S VR SureScan ICD DF1 (Product No. DVFC3D1); || d. Visia AF MRI VR SureScan DF4 (Product No. DVFC3D4) || Implantable devices that automatically detect and treat episodes of ventricular fibrillation, ventricular tachycardia, fast ventricular tachycardia, and bradyarrhythmia. Some devices can also provide resynchronization therapy, including sequential biventricular pacing (CRT-D devices).